Publications by authors named "E Miyauchi"
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML).
Methods: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed.
Article Synopsis
- The study investigates long-term outcomes of chemoimmunotherapy for extensive-stage small-cell lung cancer (ES-SCLC) using a large cohort of patients over a minimum follow-up period of 3 years.
- Most participants were trial-eligible, with significantly better overall survival rates compared to those who were not, highlighting the impact of eligibility criteria on treatment effectiveness.
- The results underscore the practical implications of long-term outcomes in real-world settings, aiding clinical decisions for managing ES-SCLC patients.
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK + NSCLC) patient-derived cells. After drug-screening 3114 compounds, pan-HER inhibitors (ErbB pathway) and tankyrase1/2 inhibitors (Wnt/β-catenin signaling) emerged as top candidates to inhibit alectinib-induced DTP cells growth.
View Article and Find Full Text PDFArticle Synopsis
- Researchers explored the connection between DNA repair gene polymorphisms, specifically in base excision repair (BER) genes, and the risk of developing acute myeloid leukemia (AML).
- A significant association was found between the APEX1-656 T>G polymorphism and AML risk, with elevated expression of APEX1 observed in AML patients compared to healthy controls.
- The study concluded that APEX1 polymorphisms may be a risk factor for AML and emphasized APEX1's role in controlling AML cell differentiation and growth.
Article Synopsis
- Immune checkpoint inhibitors combined with chemotherapy (ICI-chemo) are a standard treatment for non-small cell lung cancer (NSCLC), but the effectiveness compared to ipilimumab and nivolumab (I-N) for patients with a PD-L1 tumor proportion score (TPS) of 1-49% was not previously assessed.
- A study involving 401 NSCLC patients analyzed treatment outcomes, finding that median overall survival (OS) was similar between the ICI-chemo group (21.0 months) and the I-N group (20.0 months), with no significant survival differences after matching for confounders.
- However, in patients with a TPS of 25-49%, the ICI-chemo group showed a